For years, European medical-device strategy has been dominated by implementation of the Medical Device Regulation (MDR) and In Vitro Diagnostic Medical Device Regulation (IVDR). The next chapter may be about making that system more workable.
The European Commission proposed targeted amendments in December 2025 to simplify and reduce the burden of MDR and IVDR rules. The proposal also touches the European Medicines Agency's support for medical-device expert panels and the relationship with the EU AI Act. This is an ongoing regulatory process, not a newly enacted rule this week.
Why simplification matters
Regulation has to perform two jobs that can pull in different directions: protect patients and enable useful technologies to reach them. Excessive friction can increase cost, delay market entry and disproportionately affect smaller manufacturers. Too little oversight can expose patients and health systems to unacceptable risk.
The Commission's proposal is important because it acknowledges regulatory burden itself as a market-access variable. For a manufacturer, commercialization is not simply a question of demand. It includes conformity assessment, notified-body capacity, evidence, post-market obligations, classification and increasingly the interaction between device and AI rules.
Regulatory strategy is no longer a function that begins after product development. In Europe, product design, evidence strategy, AI functionality and commercialization planning increasingly need to be considered together.
The AI intersection
Software and AI-enabled medical technologies can sit at the intersection of multiple regulatory regimes. That creates the possibility of duplicated processes, unclear responsibilities or requirements that were designed under different assumptions. The simplification discussion therefore matters beyond traditional hardware manufacturers.
What manufacturers should do now
Companies should avoid treating proposed simplification as deregulation or assuming future amendments before they are adopted. Instead, they should map their current MDR/IVDR pathway, identify areas where the proposal could materially affect cost or timing, and follow the legislative process closely.
What to watch
Watch negotiations among EU institutions, implementation timelines, changes affecting notified-body interactions and any clarification of the relationship between medical-device requirements and the AI Act.
European expansion requires more than identifying a distributor. Regulatory readiness, reimbursement, clinical evidence, channel strategy and local operational partners must align. Simplification may reduce friction, but it does not eliminate the need for an integrated market-access strategy.